InFocus Capital Partners Completes Series A Investment in Qura, Inc.

LONG ISLAND, N.Y., Jan. 31, 2018 -- InFocus Capital Partners (http://infocuscapitalpartners.com), an investment firm specializing in the identification and commercialization of ophthalmic health care innovations, has provided a Series A round of funding for Qura Inc., to advance the QSmart wireless implantable pressure sensor technology and monitoring system.

logo

QSmart will improve medical and surgical management of glaucoma by providing 24/7 monitoring, pressure event detection and real time intraocular pressure (IOP) updates.  This micro-sized wireless implantable pressure sensor can be programmed to the physician’s exact specifications to monitor and collect the most relevant data concerning IOP changes.  The information is then delivered to a handheld device or tablet, allowing physicians to evaluate the effectiveness of current glaucoma treatment for their patients in real-time.

“InFocus Capital Partners is excited to support this breakthrough approach to biomedical pressure measurement and monitoring for glaucoma,” said Robert Rothman, MD, Managing Director.  “As ophthalmologists investing in technologies to improve eyecare, it was easy for us to recognize Qura as exactly the type of company we were looking for to help advance and commercialize.”

Dr. Rothman and his founding partner, Dr. Ron Weiss, at InFocus are both academically-affiliated and board-certified ophthalmologists.

“What makes this minimally invasive micro-implant and monitoring system so unique is that it will operate autonomously regardless of patient activity,” said Douglas Adams, President and Co-founder of Qura. “Glaucoma, a leading cause of vision loss and blindness, is largely undertreated due to poor patient compliance. With QSmart, physicians will now have relevant, targeted data to determine the best treatment plans for the patient and information to help patients achieve increased compliance.”

Glaucoma is a disease of the eye in which excess fluid buildup causes high intraocular pressure (IOP), leading to damage to the optic nerve that may result in vision loss and ultimately, blindness.  Implantable continuous monitoring can lead to much earlier detection and better management of glaucoma, thereby improving patient care and reducing healthcare costs.

About InFocus Capital Partners

InFocus Capital Partners (http://infocuscapitalpartners.com) is a venture capital fund specializing in the identification, capitalization and development of breakthrough and disruptive opportunities in the ophthalmic space.  The team and advisors at InFocus are accomplished ophthalmologists, ophthalmic executives, and seasoned finance professionals who are well-positioned to understand and evaluate life-science investments. 

For more information about InFocus Capital Partners, please contact Robert Rothman, MD at [email protected].

About Qura, Inc.

Qura, Inc. has developed QSmart, the first Wireless Implantable Pressure Sensor (WIPS) and Monitoring System for glaucoma.  This active, wireless and continuous eye pressure sensor collects actionable data in real time, facilitating timely and targeted medical or surgical intervention.  QSmart has the potential to help the more than 80 million people throughout the world affected by glaucoma.

For more information about Qura, please contact Douglas Adams at [email protected] or (978) 808-6926.

A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dd02f436-6c83-4276-9060-6d473aed4b2e